Emerging treatments in alopecia

Expert Opinion on Emerging Drugs

Volumn 19, Issue 4, 2014, Pages 545-556

  Falto Aizpurua, Leyre ^a   Choudhary, Sonal ^a   Tosti, Antonella ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Abatacept; Alopecia areata; Androgenetic alopecia; Bimatoprost; Chemotherapy induced alopecia; Dutasteride; Excimer laser; Finasteride; Hair transplant; IL 2; Iron; Janus kinase inhibitors; Micropigmentation; Minoxidil; Pioglitazone; Platelet rich plasma; Prostaglandin; Retinoids; Ruxolitinib; Scalp cooling; Scarring alopecia; Stem cells; Tofacitinib; Trichotillomania; Vitamin D; Wnt pathway

Indexed keywords

ABATACEPT; ACETYLCYSTEINE; ANTINEOPLASTIC AGENT; BIMATOPROST; CETIRIZINE; DUTASTERIDE; FINASTERIDE; GROWTH FACTOR; HORMONE RECEPTOR AFFECTING AGENT; INOSITOL; INTERLEUKIN 2; IRON; JANUS KINASE INHIBITOR; METHOTREXATE; MINOXIDIL; NALTREXONE; OLANZAPINE; PIOGLITAZONE; PROSTAGLANDIN; RETINOIC ACID; RETINOL; RUXOLITINIB; VASOCONSTRICTOR AGENT; VITAMIN D; JANUS KINASE;

ALOPECIA; ALOPECIA AREATA; BIOFILM; CLINICAL TRIAL (TOPIC); COOLING; DIET SUPPLEMENTATION; DRUG DELIVERY SYSTEM; DRUG SCREENING; DRUG TARGETING; EXCIMER LASER; FOLLICULITIS; HAIR FOLLICLE; HAIR TRANSPLANTATION; HUMAN; MALE TYPE ALOPECIA; MEDICAL RESEARCH; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLATELET-RICH PLASMA CELL; REVIEW; SKIN PIGMENTATION; STEM CELL; THROMBOCYTE RICH PLASMA; TRICHOTILLOMANIA; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; ANIMAL; ANTAGONISTS AND INHIBITORS; HAIR; METABOLISM; PATHOPHYSIOLOGY; PROCEDURES; STEM CELL TRANSPLANTATION; TRANSPLANTATION;

ALOPECIA; ALOPECIA AREATA; ANIMALS; HAIR; HAIR FOLLICLE; HUMANS; JANUS KINASES; STEM CELL TRANSPLANTATION;

EID: 84912097925     PISSN: 14728214     EISSN: 17447623     Source Type: Journal    
DOI: 10.1517/14728214.2014.974550     Document Type: Review

References (83)

1. Mubki T, Rudnicka L, Olszewska M, Shapiro J. Evaluation and diagnosis of the hair loss patient: part II. Trichoscopic and laboratory evaluations. J Am Acad Dermatol 2014;71(3):431; e431-431 e411
2. Mubki T, Rudnicka L, Olszewska M, Shapiro J. Evaluation and diagnosis of the hair loss patient: part I. History and clinical examination. J Am Acad Dermatol 2014;71(3):415; e411-415 e415
3. Miteva M, Tosti A. Treatment options for alopecia: an update, looking to the future. Expert Opin Pharmacother 2012;13(9):1271-81
4. Traish AM, Mulgaonkar A, Giordano N. The dark side of 5alpha-reductase inhibitors' therapy: sexual dysfunction, high Gleason grade prostate cancer and depression. Korean J Urol 2014;55(6):367-79
5. Shin HS, Won CH, Lee SH, et al. Efficacy of 5% minoxidil versus combined 5% minoxidil and 0.01% tretinoin for male pattern hair loss: a randomized, double-blind, comparative clinical trial. Am J Clin Dermatol 2007;8(5):285-90
6. Delamere FM, Sladden MM, Dobbins HM, Leonardi-Bee J. Interventions for alopecia areata. Cochrane Database Syst Rev 2008(2):CD004413
7. Tosti A, Iorizzo M, Botta GL, Milani M. Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial. J Eur Acad Dermatol Venereol 2006;20(10):1243-7
8. Sardesai VR, Prasad S, Agarwal TD. A study to evaluate the efficacy of various topical treatment modalities for alopecia areata. Int J Trichol 2012;4(4):265-70
9. Kar BR, Handa S, Dogra S, Kumar B. Placebo-controlled oral pulse prednisolone therapy in alopecia areata. J Am Acad Dermatol 2005;52(2):287-90
10. d'Ovidio R, Rossi A, Di Prima TM. Therapeutic hotline. Effectiveness of the association of cetirizine and topical steroids in lichen planus pilaris-an open-label clinical trial. Dermatol Ther 2010;23(5):547-52
11. Jain R, De-Eknamkul W. Potential targets in the discovery of new hair growth promoters for androgenic alopecia. Expert Opin Ther Targets 2014;18(7):787-806
12. Valente Duarte de Sousa IC, Tosti A. New investigational drugs for androgenetic alopecia. Expert Opin Investig Drugs 2013;22(5):573-89
13. Gubelin Harcha W, Barboza Martinez J, Tsai TF, et al. A randomized, active-and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol 2014;70(3):489-98; e483
14. Jung JY, Yeon JH, Choi JW, et al. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride. Int J Dermatol 2014. [Epub ahead of print]
15. Khidhir KG, Woodward DF, Farjo NP, et al. The prostamide-related glaucoma therapy, bimatoprost, offers a novel approach for treating scalp alopecias. FASEB J 2013;27(2):557-67
16. Garza LA, Liu Y, Yang Z, et al. Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Sci Transl Med 2012;4(126):126ra134
17. Nelson AM, Loy DE, Lawson JA, et al. Prostaglandin D2 inhibits wound-induced hair follicle neogenesis through the receptor, Gpr44. J Invest Dermatol 2013;133(4):881-9
18. Nieves A, Garza LA. Does prostaglandin D2 hold the cure to male pattern baldness? Exp Dermatol 2014;23(4):224-7
19. Conde Montero E, Fernandez Santos ME, Suarez Fernandez R. Platelet-rich plasma: applications in dermatology. Actas dermosifiliogr 2014. [Epub ahead of print]
20. Li ZJ, Choi HI, Choi DK, et al. Autologous platelet-rich plasma: a potential therapeutic tool for promoting hair growth. Dermatol Surg 2012;38(7 Pt 1):1040-6
21. Miao Y, Sun YB, Sun XJ, et al. Promotional effect of platelet-rich plasma on hair follicle reconstitution in vivo. Dermatol Surg 2013;39(12):1868-76
22. Uebel CO, da Silva JB, Cantarelli D, Martins P. The role of platelet plasma growth factors in male pattern baldness surgery. Plast Reconstr Surg 2006;118(6):1458-66; discussion 1467
23. Sclafani AP. Platelet-rich fibrin matrix (PRFM) for androgenetic alopecia. Facial Plast Surg 2014;30(2):219-24
24. Mokos ZB, Mosler EL. Advances in a rapidly emerging field of hair follicle stem cell research. Coll Antropol 2014;38(1):373-8
25. Mobini N, Tam S, Kamino H. Possible role of the bulge region in the pathogenesis of inflammatory scarring alopecia: lichen planopilaris as the prototype. J Cutan Pathol 2005;32(10):675-9
26. Whiting DA. Histopathologic features of alopecia areata: a new look. Arch Dermatol 2003;139(12):1555-9
27. Meyer KC, Klatte JE, Dinh HV, et al. Evidence that the bulge region is a site of relative immune privilege in human hair follicles. Br J Dermatol 2008;159(5):1077-85
28. Huelsken J, Vogel R, Erdmann B, et al. Beta-Catenin controls hair follicle morphogenesis and stem cell differentiation in the skin. Cell 2001;105(4):533-45
29. Tumbar T, Guasch G, Greco V, et al. Defining the epithelial stem cell niche in skin. Science 2004;303(5656):359-63
30. Ito M, Yang Z, Andl T, et al. Wnt-dependent de novo hair follicle regeneration in adult mouse skin after wounding. Nature 2007;447(7142):316-20
31. Claudinot S, Nicolas M, Oshima H, et al. Long-term renewal of hair follicles from clonogenic multipotent stem cells. Proc Natl Acad Sci USA 2005;102(41):14677-82
32. Cotsarelis G. Epithelial stem cells: a folliculocentric view. J Invest Dermatol 2006;126(7):1459-68
33. Cotsarelis G. Gene expression profiling gets to the root of human hair follicle stem cells. J Clin Invest 2006;116(1):19-22
34. Choi YS, Zhang Y, Xu M, et al. Distinct functions for Wnt/beta-catenin in hair follicle stem cell proliferation and survival and interfollicular epidermal homeostasis. Cell Stem Cell 2013;13(6):720-33
35. Lee SH, Yoon J, Shin SH, et al. Valproic acid induces hair regeneration in murine model and activates alkaline phosphatase activity in human dermal papilla cells. PLoS One 2012;7(4):e34152
36. Jo SJ, Choi SJ, Yoon SY, et al. Valproic acid promotes human hair growth in in vitro culture model. J Dermatol Sci 2013;72(1):16-24
37. Jo SJ, Shin H, Park YW, et al. Topical valproic acid increases the hair count in male patients with androgenetic alopecia: a randomized, comparative, clinical feasibility study using phototrichogram analysis. J Dermatol 2014;41(4):285-91
38. Jeong YM, Sung YK, Kim WK, et al. Ultraviolet B preconditioning enhances the hair growth-promoting effects of adipose-derived stem cells via generation of reactive oxygen species. Stem Cells Dev 2013;22(1):158-68
39. Toyoshima KE, Asakawa K, Ishibashi N, et al. Fully functional hair follicle regeneration through the rearrangement of stem cells and their niches. Nature Commun 2012;3:784
40. Asakawa K, Toyoshima KE, Ishibashi N, et al. Hair organ regeneration via the bioengineered hair follicular unit transplantation. Sci Rep 2012;2:424
41. Yang R, Zheng Y, Burrows M, et al. Generation of folliculogenic human epithelial stem cells from induced pluripotent stem cells. Nature Commun 2014;5:3071
42. Kumar A, Gupta S, Mohanty S, et al. Stem Cell Niche is Partially Lost during Follicular Plucking: a Preliminary Pilot Study. Int J Trichol 2013;5(2):97-100
43. Gupta A. Microrefined Microfollicular Hair Transplant: a New Modification in Hair Transplant. Ann Plast Surg 2014;73(3):257-65
44. Rashid RM. Follicular unit extraction with the Artas robotic hair transplant system system: an evaluation of FUE yield. Dermatol Online J 2014;20(4):22341
45. Bicknell LM, Kash N, Kavouspour C, Rashid RM. Follicular unit extraction hair transplant harvest: a review of current recommendations and future considerations. Dermatol Online J 2014;20:3
46. Park JH, Moh JS, Lee SY, You SH. Micropigmentation: camouflaging scalp alopecia and scars in Korean patients. Aesthetic Plast Surg 2014;38(1):199-204
47. Guo Z, Higgins CA, Gillette BM, et al. Building a microphysiological skin model from induced pluripotent stem cells. Stem Cell Res Ther 2013;4(Suppl 1):S2
48. Gomes MJ, Martins S, Ferreira D, et al. Lipid nanoparticles for topical and transdermal application for alopecia treatment: development, physicochemical characterization, and in vitro release and penetration studies. Int J Nanomedicine 2014;9:1231-42
49. Castela E, Le Duff F, Butori C, et al. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. JAMA Dermatol 2014;150(7):748-51
50. Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 2014;20(9):1043-9
51. Craiglow BG, King BA. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol 2014. [Epub ahead of print]
52. Trink A, Sorbellini E, Bezzola P, et al. A randomized, double-blind, placebo-and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata. Br J Dermatol 2013;169(3):690-4
53. Matard B, Meylheuc T, Briandet R, et al. First evidence of bacterial biofilms in the anaerobe part of scalp hair follicles: a pilot comparative study in folliculitis decalvans. J Eur Acad Dermatol Venereol 2013;27(7):853-60
54. Karnik P, Tekeste Z, McCormick TS, et al. Hair follicle stem cell-specific PPARgamma deletion causes scarring alopecia. J Invest Dermatol 2009;129(5):1243-57
55. Stenn KS, Karnik P. Lipids to the top of hair biology. J Invest Dermatol 2010;130(5):1205-7
56. Mirmirani P, Karnik P. Lichen planopilaris treated with a peroxisome proliferator-activated receptor gamma agonist. Arch Dermatol 2009;145(12):1363-6
57. Baibergenova A, Walsh S. Use of pioglitazone in patients with lichen planopilaris. J Cutan Med Surg 2012;16(2):97-100
58. Spring P, Spanou Z, de Viragh PA. Lichen planopilaris treated by the peroxisome proliferator activated receptor-gamma agonist pioglitazone: lack of lasting improvement or cure in the majority of patients. J Am Acad Dermatol 2013;69(5):830-2
59. Panicker SP, Ganguly T, Consolo M, et al. Sterol intermediates of cholesterol biosynthesis inhibit hair growth and trigger an innate immune response in cicatricial alopecia. PLoS One 2012;7(6):e38449
60. Navarini AA, Kolios AG, Prinz-Vavricka BM, et al. Low-dose excimer 308-nm laser for treatment of lichen planopilaris. Arch Dermatol 2011;147(11):1325-6
61. Komen MM, Smorenburg CH, van den Hurk CJ, Nortier JW. Factors influencing the effectiveness of scalp cooling in the prevention of chemotherapy-induced alopecia. Oncologist 2013;18(7):885-91
62. Ekwall EM, Nygren LM, Gustafsson AO, Sorbe BG. Determination of the most effective cooling temperature for the prevention of chemotherapy-induced alopecia. Mol Clin Oncol 2013;1(6):1065-71
63. Betticher DC, Delmore G, Breitenstein U, et al. Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatment. Support Care Cancer 2013;21(9):2565-73
64. Soref CM, Fahl WE. A new strategy to prevent chemotherapy and radiotherapy-induced alopecia using topically applied vasoconstrictor. Int J Cancer 2014. [Epub ahead of print]
65. Katikaneni R, Ponnapakkam T, Matsushita O, et al. Treatment and prevention of chemotherapy-induced alopecia with PTH-CBD, a collagen-targeted parathyroid hormone analog, in a non-depilated mouse model. Anticancer Drugs 2014;25(1):30-8
66. Grant JE, Odlaug BL, Kim SW. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2009;66(7):756-63
67. Taylor M, Bhagwandas K. N-Acetylcysteine in Trichotillomania-A panacea for compulsive skin disorders? Br J Dermatol 2014. [Epub ahead of print]
68. Van Ameringen M, Mancini C, Patterson B, et al. A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. J Clin Psychiatry 2010;71(10):1336-43
69. Grant JE, Odlaug BL, Schreiber LR, Kim SW. The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. J Clin Psychopharmacol 2014;34(1):134-8
70. De Sousa A. An open-label pilot study of naltrexone in childhood-onset trichotillomania. J Child Adolesc Psychopharmacol 2008;18(1):30-3
71. Park SY, Na SY, Kim JH, et al. Iron plays a certain role in patterned hair loss. J Korean Med Sci 2013;28(6):934-8
72. Rasheed H, Mahgoub D, Hegazy R, et al. Serum ferritin and vitamin d in female hair loss: do they play a role? Skin Pharmacol Physiol 2013;26(2):101-7
73. Mahamid M, Abu-Elhija O, Samamra M, et al. Association between vitamin D levels and alopecia areata. Isr Med Assoc J 2014;16(6):367-70
74. Aksu Cerman A, Sarikaya Solak S, Kivanc Altunay I. Vitamin D deficiency in alopecia areata. Br J Dermatol 2014;170(6):1299-304
75. d'Ovidio R, Vessio M, d'Ovidio FD. Reduced level of 25-hydroxyvitamin D in chronic/relapsing Alopecia Areata. Dermatoendocrinol 2013; 5(2): 271-3
76. Demay MB. Physiological insights from the vitamin D receptor knockout mouse. Calcif Tissue Int 2013;92(2):99-105
77. Lim YY, Kim SY, Kim HM, et al. Potential relationship between the canonical Wnt signalling pathway and expression of the vitamin D receptor in alopecia. Clin Exp Dermatol 2014;39(3):368-75
78. Holler PD, Cotsarelis G. Retinoids putting the "a" in alopecia. J Invest Dermatol 2013;133(2):285-6
79. Duncan FJ, Silva KA, Johnson CJ, et al. Endogenous retinoids in the pathogenesis of alopecia areata. J Invest Dermatol 2013;133(2):334-43
80. Everts HB. Endogenous retinoids in the hair follicle and sebaceous gland. Biochim Biophys Acta 2012;1821(1):222-9
81. Moreland L, Bate G, Kirkpatrick P. Abatacept. Nat Rev Drug Discov 2006;5(3):185-6
82. d'Ovidio R, Roberto M. Limited effectiveness of platelet-rich-plasma treatment on chronic severe alopecia areata. Hair Ther Transplant 2014; 4: 116
83. Caserini M, Radicioni M, Leuratti C, et al. A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. Int J Clin Pharmacol Ther 2014;52(10):842-9